Research Topics
| Grit ZahnSummaryCountry: Germany Publications
| Collaborators
|
Detail Information
Publications
Preclinical evaluation of the novel small-molecule integrin alpha5beta1 inhibitor JSM6427 in monkey and rabbit models of choroidal neovascularizationGrit Zahn
Jerini AG, Invalidenstrasse 130, 10115 Berlin, Germany
Arch Ophthalmol 127:1329-35. 2009..To evaluate the pharmacologic activity and tolerability of JSM6427, a potent and first selective small-molecule inhibitor of integrin alpha5beta1, in monkey and rabbit models of choroidal neovascularization (CNV)...
Assessment of the integrin alpha5beta1 antagonist JSM6427 in proliferative vitreoretinopathy using in vitro assays and a rabbit model of retinal detachmentGrit Zahn
Jerini AG, Berlin, Germany
Invest Ophthalmol Vis Sci 51:1028-35. 2010....
SAR of N-phenyl piperidine based oral integrin alpha5beta1 antagonistsGunther Zischinsky
Jerini AG, Invalidenstrasse 130, Berlin D 10115, Germany
Bioorg Med Chem Lett 20:65-8. 2010..Recently, a new class of selective integrin alpha5beta1inhibitors consisting of a heterocyclic based scaffold was published. Herein the SAR and pharmacokinetic profiles of N-phenyl piperidine derivatives are described...
Discovery of orally available integrin alpha5beta1 antagonistsGunther Zischinsky
Jerini AG, Invalidenstrasse 130, Berlin D 10115, Germany
Bioorg Med Chem Lett 20:380-2. 2010..Herein the discovery of new orally available integrin alpha5beta1 inhibitor scaffolds for potential systemic treatment is described...
Design and synthesis of a new class of selective integrin alpha5beta1 antagonistsRoland Stragies
Jerini AG, Invalidenstrasse 130, D 10115 Berlin, Germany
J Med Chem 50:3786-94. 2007..On the basis of the encouraging results from various in vitro studies, the most active compounds were selected for further in vivo studies in animal models and preclinical development...
